Julie Jesson1, Désiré L Dahourou2, Françoise Renaud3, Martina Penazzato3, Valériane Leroy4. 1. Inserm, U897, University of Bordeaux, ISPED, Bordeaux, France. 2. Centre de Recherche Internationale pour la Santé, Projet MONOD ANRS 12206, Ouagadougou, Burkina Faso. 3. Department of HIV/AIDS, WHO, Geneva, Switzerland. 4. Inserm, U897, University of Bordeaux, ISPED, Bordeaux, France. Electronic address: valeriane.leroy@inserm.fr.
Abstract
BACKGROUND: Concerns exist about the toxicity of drugs used in the implementation of large-scale antiretroviral programmes, and documentation of antiretroviral toxicity is essential. We did a systematic review and meta-analysis of adverse events among children and adolescents receiving regimens that contain abacavir, a widely used antiretroviral drug. METHODS: We searched bibliographic databases and abstracts from relevant conferences from Jan 1, 2000, to March 1, 2015. All experimental and observational studies of HIV-infected patients aged 0-18 years who used abacavir, were eligible. Incidence of adverse outcomes in patients taking abacavir (number of new events in a period divided by population at risk at the beginning of the study) and relative risks (RR) compared with non-abacavir regimens were pooled with random effects models. FINDINGS: Of 337 records and 21 conference abstracts identified, nine studies (eight full-text articles and one abstract) collected information about 2546 children, of whom 1769 (69%) were on abacavir regimens. Among children and adolescents taking abacavir, hypersensitivity reactions (eight studies) had a pooled incidence of 2·2% (95% CI 0·4-5·2); treatment switching or discontinuation (seven studies) pooled incidence was 10·9% (2·1-24·3); of grade 3-4 adverse events (six studies) pooled incidence was 9·9% (2·4-20·9); and adverse events other than hypersensitivity reaction (six studies) pooled incidence was 21·5% (2·8-48·4). Between-study inconsistency was significant for all outcomes (p<0·0001 for all inconsistencies). Incidence of death (four studies) was 3·3% (95% CI 1·5-5·6). In the three randomised clinical trials with comparative data, no increased risk of hypersensitivity reaction (pooled RR 1·08; 95% CI 0·19-6·15), grade 3 or 4 events (0·79 [0·44-1·42]), or death (1·72 [0·77-3·82]) was noted for abacavir relative to non-abacavir regimens. None of the reported deaths were related to abacavir. INTERPRETATION: Abacavir-related toxicity occurs early after ART initiation and is manageable. Abacavir can be safely used for first-line or second-line antiretroviral regimens in children and adolescents, especially in sub-Saharan Africa were HLA B5701 genotype is rare. FUNDING: WHO.
BACKGROUND: Concerns exist about the toxicity of drugs used in the implementation of large-scale antiretroviral programmes, and documentation of antiretroviral toxicity is essential. We did a systematic review and meta-analysis of adverse events among children and adolescents receiving regimens that contain abacavir, a widely used antiretroviral drug. METHODS: We searched bibliographic databases and abstracts from relevant conferences from Jan 1, 2000, to March 1, 2015. All experimental and observational studies of HIV-infected patients aged 0-18 years who used abacavir, were eligible. Incidence of adverse outcomes in patients taking abacavir (number of new events in a period divided by population at risk at the beginning of the study) and relative risks (RR) compared with non-abacavir regimens were pooled with random effects models. FINDINGS: Of 337 records and 21 conference abstracts identified, nine studies (eight full-text articles and one abstract) collected information about 2546 children, of whom 1769 (69%) were on abacavir regimens. Among children and adolescents taking abacavir, hypersensitivity reactions (eight studies) had a pooled incidence of 2·2% (95% CI 0·4-5·2); treatment switching or discontinuation (seven studies) pooled incidence was 10·9% (2·1-24·3); of grade 3-4 adverse events (six studies) pooled incidence was 9·9% (2·4-20·9); and adverse events other than hypersensitivity reaction (six studies) pooled incidence was 21·5% (2·8-48·4). Between-study inconsistency was significant for all outcomes (p<0·0001 for all inconsistencies). Incidence of death (four studies) was 3·3% (95% CI 1·5-5·6). In the three randomised clinical trials with comparative data, no increased risk of hypersensitivity reaction (pooled RR 1·08; 95% CI 0·19-6·15), grade 3 or 4 events (0·79 [0·44-1·42]), or death (1·72 [0·77-3·82]) was noted for abacavir relative to non-abacavir regimens. None of the reported deaths were related to abacavir. INTERPRETATION: Abacavir-related toxicity occurs early after ART initiation and is manageable. Abacavir can be safely used for first-line or second-line antiretroviral regimens in children and adolescents, especially in sub-Saharan Africa were HLA B5701 genotype is rare. FUNDING: WHO.
Authors: Adrie Bekker; Edmund V Capparelli; Avy Violari; Mark F Cotton; Mae Cababasay; Jiajia Wang; Ruth Mathiba; Lubbe Wiesner; Andrew Wiznia; Pearl Samson; Renee Browning; Jack Moye; Firdose L Nakwa; Eric Decloedt; Helena Rabie; Mark Mirochnick; Tim R Cressey Journal: Lancet HIV Date: 2021-12-06 Impact factor: 16.070
Authors: Adrie Bekker; Helena Rabie; Nicolas Salvadori; Samantha du Toit; Kanchana Than-In-At; Marisa Groenewald; Isabelle Andrieux-Meyer; Mukesh Kumar; Ratchada Cressey; James Nielsen; Edmund Capparelli; Marc Lallemant; Mark F Cotton; Tim R Cressey Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Julie Jesson; Laura Saint-Lary; Marc Harris Dassi Tchoupa Revegue; John O'Rourke; Claire L Townsend; Françoise Renaud; Martina Penazzato; Valériane Leroy Journal: Lancet Child Adolesc Health Date: 2022-09-02
Authors: Anne Derache; Collins C Iwuji; Siva Danaviah; Jennifer Giandhari; Anne-Geneviève Marcelin; Vincent Calvez; Tulio de Oliveira; François Dabis; Deenan Pillay; Ravindra K Gupta Journal: J Antimicrob Chemother Date: 2019-02-01 Impact factor: 5.790